2024-02-01 15:06:04 ET
Summary
- Eurofins Scientific is delivering a 10% growth without relying on exuberant COVID-related margins.
- The company boasts a robust business model, a significant market share, and a reliable and trustworthy management team.
- The stock has the potential to double by 2028 if the management projections are achieved.
- The current price is roughly 30% below my valuation.
Eurofins Scientific (ERFSF) is a growth story. The current stock price has experienced a 55% decline from its COVID peak; however, the company continues to exhibit a steady 10% annual growth rate, even without the exceptional COVID-related margins. I am positively inclined toward the business model, management approach, and growth potential. Consequently, I believe the company is reasonably valued, making it a good buying opportunity.
If you're considering buying the stock, I recommend doing so on Euronext Paris, where it is traded under the ticker ERF and has higher trading volume compared to the US....
Read the full article on Seeking Alpha
For further details see:
Eurofins Scientific Is A Growth Story That Has Reached Fair Valuation Again